OKYO Pharma Limited (OKYO) has a negative trailing P/E of -12.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -7.88%.
Criteria proven by this page:
Overall SharesGrow Score: 39/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -21.0 | 0.24 | 0.54 | 0.00 | - |
| 2017 | -87.4 | 1.15 | 0.00 | 0.00 | - |
| 2018 | -0.8 | 0.00 | 0.00 | 0.00 | - |
| 2019 | -5.8 | 0.07 | 85.91 | 0.00 | - |
| 2020 | -21.5 | 0.30 | -237.22 | 0.00 | - |
| 2021 | -11.2 | -0.13 | 7.04 | 0.00 | - |
| 2022 | -10.0 | -0.80 | 18.50 | 0.00 | - |
| 2023 | -2.8 | -0.04 | -18.21 | 0.00 | - |
| 2024 | -2.6 | 0.03 | -7.34 | 0.00 | - |
| 2025 | -10.7 | 0.00 | -9.04 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.14 | $0.00 | $-820K | - |
| 2017 | $-0.04 | $0.00 | $-243K | - |
| 2018 | $-4.80 | $0.00 | $-28.3M | - |
| 2019 | $-0.62 | $0.00 | $-4.9M | - |
| 2020 | $-0.17 | $0.00 | $-1.54M | - |
| 2021 | $-0.32 | $0.00 | $-3.35M | - |
| 2022 | $-0.36 | $0.00 | $-5.43M | - |
| 2023 | $-0.60 | $0.00 | $-13.27M | - |
| 2024 | $0.00 | $0.00 | $-16.83K | - |
| 2025 | $-0.12 | $0.00 | $-4.71M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.19 | $-0.22 – $-0.15 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-0.24 | $-0.24 – $-0.24 | $0.00 | $0.00 – $0.00 | 1 |
| 2028 | $-0.59 | $-0.59 – $-0.59 | $11M | $11M – $11M | 1 |
| 2029 | $-0.52 | $-0.75 – $-0.29 | $32.2M | $32.2M – $32.2M | 2 |
| 2030 | $-0.28 | $-0.28 – $-0.28 | $55.2M | $55.2M – $55.2M | 1 |
